Sep 08, 2022
– Study achieved primary endpoint of Worst Itch-Numeric Rating Scale score change from baseline at Week 8 (p=0.001) – – Significant reduction of itch intensity was evident at Day 1 and effect was maintained through Week 8 – – Significantly greater proportion of patients who received oral
Additional Formats
Aug 08, 2022
– Net revenue was $23M for 2Q 2022 comprised of profit-sharing revenue of $8M from KORSUVA ™ (difelikefalin) injection and a $15M milestone payment from the European Commission approval of Kapruvia ® (difelikefalin) – – KOMFORT Phase 2 trial met primary endpoint in notalgia paresthetica, validating
Additional Formats
Displaying 1 - 10 of 26
email alerts